|
||||||
|
 | |
| |
| Differntial gene expression between RNA A-to-I edited tumor samples versus normal samples |
| |
| |
| The effects of the RNA editing to the stability of the RNA structures |
| |
| |
| |
| |
|
Editing gene: VEGFA (CAeditome ID:7422) |
Gene summary for VEGFA |
 Gene summary |
| Gene information | Gene symbol | VEGFA | Gene ID | 7422 |
| Gene name | vascular endothelial growth factor A | |
| Synonyms | MVCD1|VEGF|VPF | |
| Cytomap | 6p21.1 | |
| Type of gene | protein-coding | |
| Description | vascular endothelial growth factor Avascular endothelial growth factor A121vascular endothelial growth factor A165vascular permeability factor | |
| Modification date | 20210531 | |
| UniProtAcc | P15692 | |
| Context | - 34118146(FGF21 promotes wound healing of rat brain microvascular endothelial cells through facilitating TNF-alpha-mediated VEGFA and ERK1/2 signaling pathway.) |
| Gene ontology of each this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Gene | GO ID | GO term | PubMed ID |
| VEGFA | GO:0042531 | Vascular endothelial growth factor A | 19390056 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 12714610 |
| VEGFA | GO:0010749 | Vascular endothelial growth factor A | 16150726 |
| VEGFA | GO:0071456 | Vascular endothelial growth factor A | 10575000 |
| VEGFA | GO:0001968 | Vascular endothelial growth factor A | 14570917 |
| VEGFA | GO:0005125 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0008083 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0008083 | Vascular endothelial growth factor A | 9202027 |
| VEGFA | GO:0008201 | Vascular endothelial growth factor A | 15001987 |
| VEGFA | GO:0042056 | Vascular endothelial growth factor A | 17082651 |
| VEGFA | GO:0042056 | Vascular endothelial growth factor A | 18059339 |
| VEGFA | GO:0042056 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0042056 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0042056 | Vascular endothelial growth factor A | 21245381 |
| VEGFA | GO:0000122 | Vascular endothelial growth factor A | 18093989 |
| VEGFA | GO:0001525 | Vascular endothelial growth factor A | 11427521 |
| VEGFA | GO:0001525 | Vascular endothelial growth factor A | 21771332 |
| VEGFA | GO:0001666 | Vascular endothelial growth factor A | 16490744 |
| VEGFA | GO:0001934 | Vascular endothelial growth factor A | 18386220 |
| VEGFA | GO:0001934 | Vascular endothelial growth factor A | 19033661 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 10022831 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 16489009 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 18386220 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 18577655 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0001938 | Vascular endothelial growth factor A | 9202027 |
| VEGFA | GO:0002042 | Vascular endothelial growth factor A | 18059339 |
| VEGFA | GO:0002042 | Vascular endothelial growth factor A | 20660291 |
| VEGFA | GO:0002092 | Vascular endothelial growth factor A | 20660291 |
| VEGFA | GO:0008284 | Vascular endothelial growth factor A | 7929439 |
| VEGFA | GO:0008360 | Vascular endothelial growth factor A | 10527820 |
| VEGFA | GO:0008360 | Vascular endothelial growth factor A | 7929439 |
| VEGFA | GO:0010595 | Vascular endothelial growth factor A | 10022831 |
| VEGFA | GO:0010595 | Vascular endothelial growth factor A | 19033661 |
| VEGFA | GO:0010628 | Vascular endothelial growth factor A | 18386220 |
| VEGFA | GO:0010629 | Vascular endothelial growth factor A | 28977001 |
| VEGFA | GO:0010629 | Vascular endothelial growth factor A | 28977001 |
| VEGFA | GO:0030224 | Vascular endothelial growth factor A | 21149635 |
| VEGFA | GO:0030225 | Vascular endothelial growth factor A | 21149635 |
| VEGFA | GO:0030335 | Vascular endothelial growth factor A | 17470632 |
| VEGFA | GO:0030335 | Vascular endothelial growth factor A | 7929439 |
| VEGFA | GO:0031334 | Vascular endothelial growth factor A | 16489009 |
| VEGFA | GO:0031334 | Vascular endothelial growth factor A | 19033661 |
| VEGFA | GO:0031954 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0032147 | Vascular endothelial growth factor A | 18059339 |
| VEGFA | GO:0032147 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0032793 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0033138 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0033138 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0035148 | Vascular endothelial growth factor A | 19033661 |
| VEGFA | GO:0035767 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0035924 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0035924 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0038033 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0038033 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0038033 | Vascular endothelial growth factor A | 21245381 |
| VEGFA | GO:0038091 | Vascular endothelial growth factor A | 17470632 |
| VEGFA | GO:0043117 | Vascular endothelial growth factor A | 26598555 |
| VEGFA | GO:0043154 | Vascular endothelial growth factor A | 18386220 |
| VEGFA | GO:0043406 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0043536 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0043536 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0043536 | Vascular endothelial growth factor A | 9202027 |
| VEGFA | GO:0045766 | Vascular endothelial growth factor A | 18440775 |
| VEGFA | GO:0045766 | Vascular endothelial growth factor A | 18577655 |
| VEGFA | GO:0045766 | Vascular endothelial growth factor A | 19033661 |
| VEGFA | GO:0045766 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0045785 | Vascular endothelial growth factor A | 19674970 |
| VEGFA | GO:0045944 | Vascular endothelial growth factor A | 18059339 |
| VEGFA | GO:0048010 | Vascular endothelial growth factor A | 1312256 |
| VEGFA | GO:0048010 | Vascular endothelial growth factor A | 21245381 |
| VEGFA | GO:0048010 | Vascular endothelial growth factor A | 7929439 |
| VEGFA | GO:0050731 | Vascular endothelial growth factor A | 10022831 |
| VEGFA | GO:0050731 | Vascular endothelial growth factor A | 16489009 |
| VEGFA | GO:0050731 | Vascular endothelial growth factor A | 20048167 |
| VEGFA | GO:0050731 | Vascular endothelial growth factor A | 21245381 |
| VEGFA | GO:0050731 | Vascular endothelial growth factor A | 26598555 |
| VEGFA | GO:0050918 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:0050927 | Vascular endothelial growth factor A | 12744932 |
| VEGFA | GO:0050927 | Vascular endothelial growth factor A | 7929439 |
| VEGFA | GO:0051272 | Vascular endothelial growth factor A | 10527820 |
| VEGFA | GO:0051272 | Vascular endothelial growth factor A | 12744932 |
| VEGFA | GO:0051894 | Vascular endothelial growth factor A | 16489009 |
| VEGFA | GO:0090037 | Vascular endothelial growth factor A | 18059339 |
| VEGFA | GO:0090050 | Vascular endothelial growth factor A | 20551324 |
| VEGFA | GO:0097533 | Vascular endothelial growth factor A | 26299712 |
| VEGFA | GO:1900086 | Vascular endothelial growth factor A | 20660291 |
| VEGFA | GO:1900745 | Vascular endothelial growth factor A | 18386220 |
| VEGFA | GO:1901727 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:1903141 | Vascular endothelial growth factor A | 20048167 |
| VEGFA | GO:1903392 | Vascular endothelial growth factor A | 26598555 |
| VEGFA | GO:1903572 | Vascular endothelial growth factor A | 20497126 |
| VEGFA | GO:1903672 | Vascular endothelial growth factor A | 26299712 |
| VEGFA | GO:2000048 | Vascular endothelial growth factor A | 26598555 |
| VEGFA | GO:0005615 | Vascular endothelial growth factor A | 16490744 |
| VEGFA | GO:0005615 | Vascular endothelial growth factor A | 9202027 |
| VEGFA | GO:0005737 | Vascular endothelial growth factor A | 17082651 |
| VEGFA | GO:0005912 | Vascular endothelial growth factor A | 26598555 |
| VEGFA | GO:0009986 | Vascular endothelial growth factor A | 17470632 |
| VEGFA | GO:0030141 | Vascular endothelial growth factor A | 17082651 |
Top |
RNA A-to-I events for VEGFA |
| RNA A-to-I editing events across TCGA 33 cancers data sets based on Ensembl gene isoform structure. |
 |
| RNA editing frequencies across 33 cancers of gene: ENSG00000112715.19 |
| RNA A-to-I editing events in Cancer. |
| CAediting_485327(43772318, +), CAediting_485328(43774373, +), CAediting_485329(43780232, +), |
Top |
RNA editing positional annotations for VEGFA using Annovar |
| Protein coding RNA editing(s). |
| CAeditome ID | Position | Variant type | ENST | NTchange | AAchange | SIFT_score | Polyphen2_HVAR_score | PROVEAN_pred |
| Gene structure information of RNA editing(s). |
| CAeditome ID | Position | Variant type |
| CAediting_485327 | chr6_43772318_+ | ncRNA_intronic |
| CAediting_485328 | chr6_43774373_+ | exonic |
| CAediting_485329 | chr6_43780232_+ | ncRNA_exonic |
| Repat-regional RNA editing(s). |
| CAeditome ID | Position | Repeat family | Repeat sub family | Repeat name |
Top |
RNA A-to-I editing events in the alternative splicing sites for VEGFA |
| RNA A-to-I editing(s) in the alternative splicing sites. |
| AStype | CAeditomID | Editing position | AS position | AS direction | Exonic location | Wildtype sequence | Wildtype splicing strength | RNA edited sequence | RNA edited splicing strength |
| Differential percent of spliced in (PSI) between RNA A-to-I edited and non-edited samples for ENSG00000112715.19.VEGFA. |
| Correlation between RNA A-to-I editing and PSI for ENSG00000112715.19.VEGFA. |
Top |
Differntial gene expression between RNA A-to-I edited versus non-edited samples for VEGFA |
| Differential gene expressions between RNA A-to-I edited and non-edited tumor samples. * The grey color means N/A. |
| Correlation between RNA A-to-I editing and gene expression. |
| - Differentially expressed gene between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
Top |
Protein coding region RNA A-to-I editings for VEGFA |
| - Lollipop plot for RNA A-to-I editings across protein structure. * Click on the image to enlarge it in a new window. |
 |
Top |
The effects of the RNA editing to the miRNA binding sites for VEGFA |
| **If you are searching a miRNA gene with RNA editing events in its seed regions, please see the search pages of miRNA targets to discover the effects of this RNA editing event to miRNA regulations. For more information, please check the files in the Download page. |
| RNA A-to-I editing in the 3'-UTR regions of mRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in the 3'-UTR regions of mRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs lost binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to the 3'-UTR region of mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_748296 | chr10_51299626_+ | ENSG00000112715.19 | ENST00000372067 | hsa-miR-605-3p | 43786040 | 43786046 | 7mer-m8 | 43786025 | 43786047 | 151 | -21.77 |
| CAediting_748296 | chr10_51299626_+ | ENSG00000112715.19 | ENST00000372064 | hsa-miR-605-3p | 43786040 | 43786046 | 7mer-m8 | 43786025 | 43786047 | 151 | -21.77 |
| CAediting_748296 | chr10_51299626_+ | ENSG00000112715.19 | ENST00000372077 | hsa-miR-605-3p | 43786040 | 43786046 | 7mer-m8 | 43786025 | 43786047 | 151 | -21.77 |
| CAediting_77128 | chr1_85133844_+ | ENSG00000112715.19 | ENST00000372067 | hsa-miR-4423-3p | 43785743 | 43785749 | 7mer-m8 | 43785730 | 43785750 | 140 | -15.12 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372067 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000425836 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_77128 | chr1_85133844_+ | ENSG00000112715.19 | ENST00000372064 | hsa-miR-4423-3p | 43785743 | 43785749 | 7mer-m8 | 43785730 | 43785750 | 140 | -15.12 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372064 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_77128 | chr1_85133844_+ | ENSG00000112715.19 | ENST00000372077 | hsa-miR-4423-3p | 43785743 | 43785749 | 7mer-m8 | 43785730 | 43785750 | 140 | -15.12 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372077 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000520948 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000523950 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000230480 | hsa-miR-6840-3p | 43784777 | 43784783 | 7mer-m8 | 43784761 | 43784784 | 155 | -32.17 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000372067 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000425836 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000372064 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000372077 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000520948 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000523950 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000230480 | hsa-miR-503-5p | 43784653 | 43784659 | 7mer-m8 | 43784641 | 43784660 | 144 | -25.43 |
| RNA A-to-I editing in miRNAs lost binding to the 3'-UTR mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_393 | chr1_1167164_+ | ENSG00000112715.19 | ENST00000372067 | hsa-miR-200b-3p | 43785859 | 43785865 | 7mer-m8 | 43785845 | 43785866 | 141 | -8.88 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000372067 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372067 | hsa-miR-6840-3p | 43785580 | 43785586 | 7mer-m8 | 43785566 | 43785587 | 152 | -23.52 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372067 | hsa-miR-6840-3p | 43785544 | 43785551 | 8mer-1a | 43785530 | 43785551 | 142 | -20.88 |
| CAediting_468389 | chr6_31355314_- | ENSG00000112715.19 | ENST00000372067 | hsa-miR-6891-5p | 43786264 | 43786269 | 6mer | 43786252 | 43786270 | 145 | -21 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000425836 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| CAediting_393 | chr1_1167164_+ | ENSG00000112715.19 | ENST00000372064 | hsa-miR-200b-3p | 43785859 | 43785865 | 7mer-m8 | 43785845 | 43785866 | 141 | -8.88 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000372064 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372064 | hsa-miR-6840-3p | 43785580 | 43785586 | 7mer-m8 | 43785566 | 43785587 | 152 | -23.52 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372064 | hsa-miR-6840-3p | 43785544 | 43785551 | 8mer-1a | 43785530 | 43785551 | 142 | -20.88 |
| CAediting_468389 | chr6_31355314_- | ENSG00000112715.19 | ENST00000372064 | hsa-miR-6891-5p | 43786264 | 43786269 | 6mer | 43786252 | 43786270 | 145 | -21 |
| CAediting_393 | chr1_1167164_+ | ENSG00000112715.19 | ENST00000372077 | hsa-miR-200b-3p | 43785859 | 43785865 | 7mer-m8 | 43785845 | 43785866 | 141 | -8.88 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000372077 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372077 | hsa-miR-6840-3p | 43785580 | 43785586 | 7mer-m8 | 43785566 | 43785587 | 152 | -23.52 |
| CAediting_580943 | chr7_100356700_+ | ENSG00000112715.19 | ENST00000372077 | hsa-miR-6840-3p | 43785544 | 43785551 | 8mer-1a | 43785530 | 43785551 | 142 | -20.88 |
| CAediting_468389 | chr6_31355314_- | ENSG00000112715.19 | ENST00000372077 | hsa-miR-6891-5p | 43786264 | 43786269 | 6mer | 43786252 | 43786270 | 145 | -21 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000520948 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000523950 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| CAediting_1524209 | chrX_134546392_- | ENSG00000112715.19 | ENST00000230480 | hsa-miR-503-5p | 43784838 | 43784844 | 7mer-1a | 43784822 | 43784844 | 148 | -19.02 |
| Differentially expressed gene-miRNA network |
Top |
The effects of the RNA editing to the stability of the RNA structures for VEGFA |
| - RNA A-to-I editing in mRNA. * Click on the image to enlarge it in a new window. |
| ENST | ENST type | RNA structure without RNA A-to-I editing. | RNA structure with RNA A-to-I editing. |
| ENST00000230480.9 | protein_coding |  |  |
| ENST00000324450.9 | protein_coding |  |  |
| ENST00000372055.7 | protein_coding |  |  |
| ENST00000372064.7 | protein_coding |  |  |
| ENST00000372067.6 | protein_coding |  |  |
| ENST00000372077.7 | protein_coding |  |  |
| ENST00000413642.6 | protein_coding |  |  |
| ENST00000417285.5 | protein_coding |  |  |
| ENST00000425836.5 | protein_coding |  |  |
| ENST00000457104.5 | protein_coding |  |  |
| ENST00000476772.4 | retained_intron |  |  |
| ENST00000482630.5 | protein_coding |  |  |
| ENST00000512683.1 | retained_intron |  |  |
| ENST00000518538.4 | retained_intron |  |  |
| ENST00000518689.4 | protein_coding |  |  |
| ENST00000518824.4 | protein_coding |  |  |
| ENST00000519767.4 | protein_coding |  |  |
| ENST00000520948.4 | protein_coding |  |  |
| ENST00000523125.4 | protein_coding |  |  |
| ENST00000523873.4 | protein_coding |  |  |
| ENST00000523950.4 | protein_coding |  |  |
| ENST00000611736.3 | protein_coding |  |  |
| ENST00000615393.3 | protein_coding |  |  |
| ENST00000617771.3 | protein_coding |  |  |
| ENST00000621747.3 | protein_coding |  |  |
| ENST00000480614.1 | retained_intron |  |  |
| ENST00000520265.1 | protein_coding |  |  |
| RNA A-to-I editing in RNA structures for Minimum free energy (MFE). |
| CAeditom_ID | ENST | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
| CAediting_485328 | ENST00000230480.9 | chr6_43774373_+ | -326.10 | -322.90 | -326.10 |
| CAediting_485328 | ENST00000324450.9 | chr6_43774373_+ | -431.10 | -431.90 | -431.10 |
| CAediting_485328 | ENST00000372055.7 | chr6_43774373_+ | -543.00 | -541.80 | -543.00 |
| CAediting_485328 | ENST00000372064.7 | chr6_43774373_+ | -1036.90 | -1037.80 | -1036.90 |
| CAediting_485328 | ENST00000372067.6 | chr6_43774373_+ | -1296.60 | -1297.50 | -1296.60 |
| CAediting_485328 | ENST00000372077.7 | chr6_43774373_+ | -1005.20 | -1006.10 | -1005.20 |
| CAediting_485328 | ENST00000413642.6 | chr6_43774373_+ | -502.90 | -503.80 | -502.90 |
| CAediting_485328 | ENST00000417285.5 | chr6_43774373_+ | -465.60 | -464.80 | -465.60 |
| CAediting_485328 | ENST00000425836.5 | chr6_43774373_+ | -617.40 | -618.10 | -617.40 |
| CAediting_485328 | ENST00000457104.5 | chr6_43774373_+ | -138.00 | -138.90 | -138.00 |
| CAediting_485328 | ENST00000476772.4 | chr6_43774373_+ | -714.50 | -711.30 | -714.50 |
| CAediting_485328 | ENST00000482630.5 | chr6_43774373_+ | -477.60 | -478.50 | -477.60 |
| CAediting_485328 | ENST00000512683.1 | chr6_43774373_+ | -184.00 | -184.80 | -184.00 |
| CAediting_485328 | ENST00000518538.4 | chr6_43774373_+ | -188.60 | -189.20 | -188.60 |
| CAediting_485328 | ENST00000518689.4 | chr6_43774373_+ | -199.10 | -200.00 | -199.10 |
| CAediting_485328 | ENST00000518824.4 | chr6_43774373_+ | -190.20 | -191.10 | -190.20 |
| CAediting_485328 | ENST00000519767.4 | chr6_43774373_+ | -396.40 | -397.30 | -396.40 |
| CAediting_485328 | ENST00000520948.4 | chr6_43774373_+ | -422.80 | -418.60 | -422.80 |
| CAediting_485328 | ENST00000523125.4 | chr6_43774373_+ | -174.70 | -175.60 | -174.70 |
| CAediting_485328 | ENST00000523873.4 | chr6_43774373_+ | -279.00 | -277.80 | -279.00 |
| CAediting_485328 | ENST00000523950.4 | chr6_43774373_+ | -319.10 | -317.80 | -319.10 |
| CAediting_485328 | ENST00000611736.3 | chr6_43774373_+ | -1344.80 | -1345.70 | -1344.80 |
| CAediting_485328 | ENST00000615393.3 | chr6_43774373_+ | -1250.40 | -1251.30 | -1250.40 |
| CAediting_485328 | ENST00000617771.3 | chr6_43774373_+ | -1248.60 | -1248.20 | -1248.60 |
| CAediting_485328 | ENST00000621747.3 | chr6_43774373_+ | -1297.10 | -1298.00 | -1297.10 |
| CAediting_485328 | ENST00000480614.1 | chr6_43774373_+ | -4922.10 | -4917.20 | -4921.80 |
| CAediting_485329 | ENST00000480614.1 | chr6_43780232_+ | -4917.50 | -4917.20 | -4921.80 |
| CAediting_485328 | ENST00000520265.1 | chr6_43774373_+ | -107.70 | -108.60 | -107.70 |
Top |
Relation with ADAR for VEGFA |
| Correlation between ADAR gene expression and RNA editing frequency |
| Cancer | CAeditomID | position | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
Top |
Relation with cancer stages for VEGFA |
| Correlation between Cancer stages and RNA editing frequency |
| Cancer | Stage_type | CAeditomID | position | P-val | Coeff. |
Top |
Relation with survival for VEGFA |
| Correlation between RNA editing and survival |
| Cancer | CAeditomID | position | KMpvalue | Coxpvalue | CoxHR |
Top |
RelatedDrugs for VEGFA |
| Approved drugs targeting this gene. (DrugBank Version 5.1.8 2021-01-03) |
| Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| VEGFA | P15692 | DB01120 | Gliclazide | Vascular endothelial growth factor A | SmallMoleculeDrug | approved |
| VEGFA | P15692 | DB01270 | Ranibizumab | Vascular endothelial growth factor A | BiotechDrug | approved |
| VEGFA | P15692 | DB05294 | Vandetanib | Vascular endothelial growth factor A | SmallMoleculeDrug | approved |
| VEGFA | P15692 | DB06779 | Dalteparin | Vascular endothelial growth factor A | SmallMoleculeDrug | approved |
| VEGFA | P15692 | DB08885 | Aflibercept | Vascular endothelial growth factor A | BiotechDrug | approved |
| VEGFA | P15692 | DB10772 | Foreskin keratinocyte (neonatal) | Vascular endothelial growth factor A | BiotechDrug | approved |
| VEGFA | P15692 | DB00112 | Bevacizumab | Vascular endothelial growth factor A | BiotechDrug | approved|investigational |
| VEGFA | P15692 | DB01017 | Minocycline | Vascular endothelial growth factor A | SmallMoleculeDrug | approved|investigational |
| VEGFA | P15692 | DB01136 | Carvedilol | Vascular endothelial growth factor A | SmallMoleculeDrug | approved|investigational |
| VEGFA | P15692 | DB03088 | Pidolic acid | Vascular endothelial growth factor A | SmallMoleculeDrug | approved|investigational |
| VEGFA | P15692 | DB04895 | Pegaptanib | Vascular endothelial growth factor A | BiotechDrug | approved|investigational |
| VEGFA | P15692 | DB14864 | Brolucizumab | Vascular endothelial growth factor A | BiotechDrug | approved|investigational |
| VEGFA | P15692 | DB09301 | Chondroitin sulfate | Vascular endothelial growth factor A | SmallMoleculeDrug | approved|investigational|nutraceutical |
Top |
RelatedDiseases for VEGFA |
| Diseases associated with this gene. (DisGeNet 7.0) |
| Gene | Disease ID | Disease name | # pubmeds | Source |
| VEGFA | C0011570 | Mental Depression | 5 | PSYGENET |
| VEGFA | C0011581 | Depressive disorder | 5 | PSYGENET |
| VEGFA | C0151744 | Myocardial Ischemia | 5 | CTD_human |
| VEGFA | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
| VEGFA | C0033578 | Prostatic Neoplasms | 4 | CTD_human |
| VEGFA | C0376358 | Malignant neoplasm of prostate | 4 | CTD_human |
| VEGFA | C0004096 | Asthma | 3 | CTD_human |
| VEGFA | C0011884 | Diabetic Retinopathy | 3 | CTD_human |
| VEGFA | C0027627 | Neoplasm Metastasis | 3 | CTD_human |
| VEGFA | C0027659 | Neoplasms, Experimental | 3 | CTD_human |
| VEGFA | C0003865 | Arthritis, Adjuvant-Induced | 2 | CTD_human |
| VEGFA | C0005586 | Bipolar Disorder | 2 | PSYGENET |
| VEGFA | C0007137 | Squamous cell carcinoma | 2 | CTD_human |
| VEGFA | C0010054 | Coronary Arteriosclerosis | 2 | CTD_human |
| VEGFA | C0018801 | Heart failure | 2 | CTD_human |
| VEGFA | C0018802 | Congestive heart failure | 2 | CTD_human |
| VEGFA | C0022660 | Kidney Failure, Acute | 2 | CTD_human |
| VEGFA | C0023212 | Left-Sided Heart Failure | 2 | CTD_human |
| VEGFA | C0023893 | Liver Cirrhosis, Experimental | 2 | CTD_human |
| VEGFA | C0027686 | Pathologic Neovascularization | 2 | CTD_human |
| VEGFA | C0235527 | Heart Failure, Right-Sided | 2 | CTD_human |
| VEGFA | C0525045 | Mood Disorders | 2 | PSYGENET |
| VEGFA | C0971858 | Arthritis, Collagen-Induced | 2 | CTD_human |
| VEGFA | C0993582 | Arthritis, Experimental | 2 | CTD_human |
| VEGFA | C1565662 | Acute Kidney Insufficiency | 2 | CTD_human |
| VEGFA | C1956346 | Coronary Artery Disease | 2 | CTD_human |
| VEGFA | C1959583 | Myocardial Failure | 2 | CTD_human |
| VEGFA | C1961112 | Heart Decompensation | 2 | CTD_human |
| VEGFA | C2609414 | Acute kidney injury | 2 | CTD_human |
| VEGFA | C0001418 | Adenocarcinoma | 1 | CTD_human |
| VEGFA | C0002152 | Alloxan Diabetes | 1 | CTD_human |
| VEGFA | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| VEGFA | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| VEGFA | C0004153 | Atherosclerosis | 1 | CTD_human |
| VEGFA | C0006118 | Brain Neoplasms | 1 | CTD_human |
| VEGFA | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| VEGFA | C0007102 | Malignant tumor of colon | 1 | CTD_human |
| VEGFA | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| VEGFA | C0007873 | Uterine Cervical Neoplasm | 1 | CTD_human |
| VEGFA | C0008677 | Bronchitis, Chronic | 1 | CTD_human |
| VEGFA | C0009375 | Colonic Neoplasms | 1 | CTD_human |
| VEGFA | C0010398 | Cruveilhier-Baumgarten Syndrome | 1 | CTD_human |
| VEGFA | C0011265 | Presenile dementia | 1 | CTD_human |
| VEGFA | C0011616 | Contact Dermatitis | 1 | CTD_human |
| VEGFA | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| VEGFA | C0011881 | Diabetic Nephropathy | 1 | CTD_human |
| VEGFA | C0013366 | Dyschondroplasias | 1 | CTD_human |
| VEGFA | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
| VEGFA | C0014556 | Epilepsy, Temporal Lobe | 1 | CTD_human |
| VEGFA | C0014558 | Uncinate Epilepsy | 1 | CTD_human |
| VEGFA | C0017636 | Glioblastoma | 1 | CTD_human |
| VEGFA | C0017667 | Nodular glomerulosclerosis | 1 | CTD_human |
| VEGFA | C0018671 | Head and Neck Neoplasms | 1 | CTD_human |
| VEGFA | C0018675 | Head Neoplasms | 1 | CTD_human |
| VEGFA | C0018798 | Congenital Heart Defects | 1 | CTD_human |
| VEGFA | C0018799 | Heart Diseases | 1 | CTD_human |
| VEGFA | C0018923 | Hemangiosarcoma | 1 | CTD_human |
| VEGFA | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| VEGFA | C0020541 | Portal Hypertension | 1 | CTD_human |
| VEGFA | C0021368 | Inflammation | 1 | CTD_human |
| VEGFA | C0023186 | Learning Disorders | 1 | CTD_human |
| VEGFA | C0023466 | Leukemia, Monocytic, Chronic | 1 | CTD_human |
| VEGFA | C0023470 | Myeloid Leukemia | 1 | CTD_human |
| VEGFA | C0023890 | Liver Cirrhosis | 1 | CTD_human |
| VEGFA | C0024115 | Lung diseases | 1 | CTD_human |
| VEGFA | C0024440 | Macular Edema, Cystoid | 1 | CTD_human |
| VEGFA | C0025237 | Melnick-Needles Syndrome | 1 | CTD_human |
| VEGFA | C0025261 | Memory Disorders | 1 | CTD_human |
| VEGFA | C0026760 | Multiple Epiphyseal Dysplasia | 1 | CTD_human |
| VEGFA | C0027055 | Myocardial Reperfusion Injury | 1 | CTD_human |
| VEGFA | C0027533 | Neck Neoplasms | 1 | CTD_human |
| VEGFA | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
| VEGFA | C0027651 | Neoplasms | 1 | CTD_human |
| VEGFA | C0029422 | Osteochondrodysplasias | 1 | CTD_human |
| VEGFA | C0029463 | Osteosarcoma | 1 | CTD_human |
| VEGFA | C0030246 | Pustulosis of Palms and Soles | 1 | CTD_human |
| VEGFA | C0032927 | Precancerous Conditions | 1 | CTD_human |
| VEGFA | C0033687 | Proteinuria | 1 | CTD_human |
| VEGFA | C0033860 | Psoriasis | 1 | CTD_human |
| VEGFA | C0035228 | Respiratory Hypersensitivity | 1 | CTD_human |
| VEGFA | C0035309 | Retinal Diseases | 1 | CTD_human |
| VEGFA | C0035328 | Retinal Vein Occlusion | 1 | CTD_human |
| VEGFA | C0035412 | Rhabdomyosarcoma | 1 | CTD_human |
| VEGFA | C0036391 | Schwartz-Jampel Syndrome | 1 | CTD_human |
| VEGFA | C0038015 | Spondyloepiphyseal Dysplasia | 1 | CTD_human |
| VEGFA | C0038220 | Status Epilepticus | 1 | CTD_human |
| VEGFA | C0038358 | Gastric ulcer | 1 | CTD_human |
| VEGFA | C0038433 | Streptozotocin Diabetes | 1 | CTD_human |
| VEGFA | C0042076 | Urologic Neoplasms | 1 | CTD_human |
| VEGFA | C0085109 | Corneal Neovascularization | 1 | CTD_human |
| VEGFA | C0085605 | Liver Failure | 1 | CTD_human |
| VEGFA | C0086692 | Benign Neoplasm | 1 | CTD_human |
| VEGFA | C0153633 | Malignant neoplasm of brain | 1 | CTD_human |
| VEGFA | C0162351 | Contact hypersensitivity | 1 | CTD_human |
| VEGFA | C0178540 | Cerebral Hypoxia-Ischemia | 1 | CTD_human |
| VEGFA | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| VEGFA | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| VEGFA | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| VEGFA | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| VEGFA | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| VEGFA | C0206726 | gliosarcoma | 1 | CTD_human |
| VEGFA | C0233794 | Memory impairment | 1 | CTD_human |
| VEGFA | C0239946 | Fibrosis, Liver | 1 | CTD_human |
| VEGFA | C0242350 | Erectile dysfunction | 1 | CTD_human |
| VEGFA | C0242383 | Age related macular degeneration | 1 | CTD_human |
| VEGFA | C0270823 | Petit mal status | 1 | CTD_human |
| VEGFA | C0271051 | Macular retinal edema | 1 | CTD_human |
| VEGFA | C0271178 | Irvine-Gass Syndrome | 1 | CTD_human |
| VEGFA | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
| VEGFA | C0278996 | Malignant Head and Neck Neoplasm | 1 | CTD_human |
| VEGFA | C0282313 | Condition, Preneoplastic | 1 | CTD_human |
| VEGFA | C0311335 | Grand Mal Status Epilepticus | 1 | CTD_human |
| VEGFA | C0334588 | Giant Cell Glioblastoma | 1 | CTD_human |
| VEGFA | C0342257 | Complications of Diabetes Mellitus | 1 | CTD_human |
| VEGFA | C0393672 | Epilepsy, Benign Psychomotor, Childhood | 1 | CTD_human |
| VEGFA | C0393682 | Epilepsy, Lateral Temporal | 1 | CTD_human |
| VEGFA | C0393734 | Complex Partial Status Epilepticus | 1 | CTD_human |
| VEGFA | C0432272 | Van Buchem disease | 1 | CTD_human |
| VEGFA | C0476089 | Endometrial Carcinoma | 1 | CTD_human |
| VEGFA | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
| VEGFA | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
| VEGFA | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
| VEGFA | C0600518 | Choroidal Neovascularization | 1 | CTD_human |
| VEGFA | C0678807 | prenatal alcohol exposure | 1 | PSYGENET |
| VEGFA | C0746787 | Cancer of Neck | 1 | CTD_human |
| VEGFA | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
| VEGFA | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
| VEGFA | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
| VEGFA | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
| VEGFA | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
| VEGFA | C0751177 | Cancer of Head | 1 | CTD_human |
| VEGFA | C0751262 | Adult Learning Disorders | 1 | CTD_human |
| VEGFA | C0751263 | Learning Disturbance | 1 | CTD_human |
| VEGFA | C0751265 | Learning Disabilities | 1 | CTD_human |
| VEGFA | C0751292 | Age-Related Memory Disorders | 1 | CTD_human |
| VEGFA | C0751293 | Memory Disorder, Semantic | 1 | CTD_human |
| VEGFA | C0751294 | Memory Disorder, Spatial | 1 | CTD_human |
| VEGFA | C0751295 | Memory Loss | 1 | CTD_human |
| VEGFA | C0751522 | Status Epilepticus, Subclinical | 1 | CTD_human |
| VEGFA | C0751523 | Non-Convulsive Status Epilepticus | 1 | CTD_human |
| VEGFA | C0751524 | Simple Partial Status Epilepticus | 1 | CTD_human |
| VEGFA | C0751571 | Cancer of Urinary Tract | 1 | CTD_human |
| VEGFA | C0752304 | Hypoxic-Ischemic Encephalopathy | 1 | CTD_human |
| VEGFA | C0752305 | Anoxic-Ischemic Encephalopathy | 1 | CTD_human |
| VEGFA | C0752306 | Anoxia-Ischemia, Brain | 1 | CTD_human |
| VEGFA | C0752307 | Anoxia-Ischemia, Cerebral | 1 | CTD_human |
| VEGFA | C0752308 | Hypoxia-Ischemia, Brain | 1 | CTD_human |
| VEGFA | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| VEGFA | C0887833 | Carcinoma, Pancreatic Ductal | 1 | CTD_human |
| VEGFA | C0887900 | Upper Aerodigestive Tract Neoplasms | 1 | CTD_human |
| VEGFA | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| VEGFA | C1330966 | Developmental Academic Disorder | 1 | CTD_human |
| VEGFA | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
| VEGFA | C1527411 | Thrombosis of retinal vein | 1 | CTD_human |
| VEGFA | C1563937 | Atherogenesis | 1 | CTD_human |
| VEGFA | C1621958 | Glioblastoma Multiforme | 1 | CTD_human |
| VEGFA | C2063866 | Depressive Disorder, Treatment-Resistant | 1 | PSYGENET |
| VEGFA | C2717961 | Thrombotic Microangiopathies | 1 | CTD_human |
| VEGFA | C2931852 | Clear-cell metastatic renal cell carcinoma | 1 | CTD_human |
| VEGFA | C2937358 | Cerebral Hemorrhage | 1 | CTD_human |
| VEGFA | C3541456 | Spondyloepiphyseal Dysplasia Tarda, X-Linked | 1 | CTD_human |
| VEGFA | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| VEGFA | C4048328 | cervical cancer | 1 | CTD_human |
| VEGFA | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| VEGFA | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| VEGFA | C4551479 | Schwartz-Jampel Syndrome, Type 1 | 1 | CTD_human |
